15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Neurogene Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $70.00 to $180.00 (about 2.6x), a sign of real disagreement on valuation. The average target of $125.00 sits 278% above the current $33.07. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.27 next quarter toward $-5.46 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Neurogene Inc.
As of Jul, 3 of 3 firms rate NGNE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NGNE EPS & revenue forecast
EPS · NEXT QUARTER
$-1.27
Range $-1.50 – $-1.06 · 6 analysts · +29% YoY
Next period, 6 analysts expect Neurogene Inc to earn $-1.27 a share (range $-1.50 – $-1.06), versus $-0.99 a year earlier. Full-year consensus is $-5.31, growing to $-5.46 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 6 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Neurogene Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NGNE.
#1
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Buy
$70.00+111.7% to target
Overall win rate
34%
+ Follow
#2
WI
Whitney Ijem
Canaccord Genuity
Buy
$180.00+444.3% to target
Coverage
—
+ Follow
#3
Sami Corwin
William Blair
Buy
No targeton NGNE
Coverage
—
+ Follow
#4
PD
Patrick Dolezal
LifeSci Capital
Buy
$60.00+81.4% to target
Coverage
—
+ Follow
#5
SS
Seema Sheoran
Rodman & Renshaw
Buy
$70.00+111.7% to target
Coverage
—
+ Follow
NGNE stock forecast FAQ
What is NGNE's average 12-month price target?+
The 2 analysts with a live target average $125.00 for Neurogene Inc over the next 12 months, ranging from a $180.00 high to a $70.00 low.
Is NGNE stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NGNE?+
The Street-high target is $180.00 (Canaccord Genuity), and the Street-low is $70.00 (HC Wainwright & Co.). The average of all 2 active targets is $125.00.
How many Wall Street analysts cover NGNE?+
3 analysts have an active rating on Neurogene Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering NGNE?+
Among analysts who currently cover NGNE, Mitchell Kapoor of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #165). Their current call is Buy with a $70.00 target.
What is Neurogene Inc's projected EPS for next quarter?+
The consensus estimate is $-1.27 per share (range $-1.50 – $-1.06) across 6 analysts. Full-year EPS is projected at $-5.31, rising to $-5.46 the following year.
How much revenue is Neurogene Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading NGNE lately?+
As of Jul, 3 of 3 firms rate NGNE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NGNE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
